Description

Cabergoline 0.25mg – ZPHC (Pack of 50 Tablets)

Description:
Cabergoline is a potent dopamine agonist that functions by stimulating D₂ dopamine receptors in the pituitary gland. This action directly inhibits the secretion of prolactin, effectively lowering serum prolactin levels . It is widely utilized in research models to manage hyperprolactinemia and conditions associated with elevated prolactin. In clinical and performance-related contexts, Cabergoline is recognized for its role in preventing and treating prolactin-induced side effects, including gynecomastia and sexual dysfunction, often linked to the use of specific anabolic agents such as Trenbolone and Nandrolone.

Mechanism of Action:
Cabergoline exerts its effects through high-affinity binding to D₂ dopamine receptors, primarily located in the anterior pituitary. This interaction suppresses the production and release of prolactin from lactotroph cells, bringing levels into the low-normal range . Beyond prolactin control, this mechanism may also positively influence neurotransmitter activity, contributing to improvements in mood, libido, and overall well-being .

Product Features:

• Potency: 0.25 mg per tablet for precise dosing.

• Presentation: Pack of 50 film-coated tablets, ensuring product stability and ease of administration.

• Quality Control: Manufactured using a GMP tablet press, with each batch verified for >= 99% API purity via HPLC (High-Performance Liquid Chromatography). Features a tamper-evident cap with a scratch-code for authenticity verification.

Key Benefits for Research Applications:

• Effective Prolactin Suppression: Activates pituitary D₂ receptors to reliably lower and control serum prolactin, preventing complications such as gynecomastia, lactation, and water retention.

• Counteraction of Prolactin-Induced Side Effects: Designed to mitigate mood swings, low libido, and other side effects associated with elevated prolactin in research models.

• Convenient Dosing Schedule: Possesses a long half-life of approximately 63-69 hours, allowing for a flexible and convenient dosing regimen of 0.25 mg twice weekly .

• Supports Research Integrity: Aids in managing hormonal imbalances to support the validity and reliability of research outcomes.

Recommended Research Protocol:
For managing prolactin levels in research settings, the standard initial dose of Cabergoline is 0.25 mg twice a week . Dosage may be titrated based on bloodwork monitoring of prolactin levels, with a typical ceiling of 1 mg per week. It is essential that dosing is strictly guided by research protocols and regular monitoring. Administration with food is advised to minimize the risk of gastrointestinal side effects.

Monitoring Advice:

• Bloodwork: Regularly track serum prolactin levels, blood pressure, and liver function .

• Clinical Observation: Monitor for mild CNS side-effects such as yawning, light-headedness, dizziness, headache, and fatigue .

• Cardiovascular Observation: Initial doses may cause postural hypotension; changing positions slowly is advised .

Potential Side Effects:
As with any potent pharmacological agent, Cabergoline is associated with certain side effects that require monitoring:

• Gastrointestinal Disturbances: Nausea, vomiting, constipation, abdominal pain, and dyspepsia .

• Cardiovascular Effects: Postural hypotension (low blood pressure) and dizziness, particularly upon initial administration .

• Neurological Effects: Headache, fatigue, somnolence, and vertigo .

• Psychiatric Effects: In rare cases, pathological gambling, increased libido, and hypersexuality have been reported, which are generally reversible upon dose reduction or discontinuation .

• Endocrine Effects: Long-term use may affect other hormone levels; regular monitoring is essential.

Contraindications:
Cabergoline is contraindicated in individuals with uncontrolled hypertension, a history of cardiac valvular disorders, pulmonary, pericardial, or retroperitoneal fibrotic disorders, or known hypersensitivity to dopamine agonists . It should not be used in cases of pregnancy-induced hypertension.

---

Frequently Asked Questions (FAQs)

1. What is Cabergoline 0.25mg primarily used for?
Cabergoline is primarily used to treat hyperprolactinemia by lowering elevated serum prolactin levels . It is also used in research to manage prolactin-related side effects associated with the use of certain anabolic steroids like Trenbolone and Nandrolone.

2. How does Cabergoline work?
It is a dopamine receptor agonist that stimulates D₂ receptors in the pituitary gland. This action directly inhibits the secretion of prolactin, thereby reducing prolactin levels in the blood .

3. What is the standard starting dose for research or clinical use?
The typical starting dose is 0.25 mg twice a week . This can be adjusted based on serum prolactin levels and individual response, but the dose should not be increased more frequently than every 4 weeks .

4. What are the common side effects of taking Cabergoline?
Common side effects include nausea, headache, dizziness (especially upon standing), fatigue, constipation, and abdominal pain . These are often most noticeable during the initial days of treatment.

5. Can Cabergoline affect blood pressure?
Yes, Cabergoline can cause a decrease in blood pressure, leading to postural hypotension (dizziness when standing up). It is advised to change positions slowly and monitor blood pressure, particularly when starting therapy .

6. What should I monitor while using Cabergoline?
It is crucial to monitor serum prolactin levels through regular bloodwork. Additionally, monitoring blood pressure and observing for any potential psychiatric or cardiac side effects is recommended. Healthcare providers may also suggest echocardiographic monitoring for long-term use .

7. Are there any psychiatric side effects associated with Cabergoline?
In rare cases, dopamine agonists like Cabergoline have been associated with pathological gambling, increased libido, and hypersexuality. These effects are typically reversible upon dose reduction or discontinuation .

8. Is Cabergoline safe for use during pregnancy or breastfeeding?
Cabergoline is generally not recommended for use during pregnancy unless the potential benefits outweigh the risks, and it should not be used during breastfeeding . It is intended for research use in this context.

9. Does Cabergoline interact with other medications?
Yes, it should not be administered with D₂ antagonists such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide. Caution is also advised when taking other medications that lower blood pressure .

10. What is the half-life of Cabergoline?
Cabergoline has an exceptionally long half-life of approximately 63 to 69 hours. This long half-life allows for convenient dosing, typically only twice a week .

---

Disclaimer: This product is intended for research purposes only. This information is for educational and informational purposes and does not constitute medical advice. Always consult with a qualified healthcare professional before using any new supplement or medication. This product is not intended to diagnose, treat, cure, or prevent any disease.

---

Secure your supply of high-quality Cabergoline ZPHC for your research needs. Ensure product authenticity and benefit from fast, reliable delivery. Visit the official site to place your order today: https://anabolicsteroidsonline.shop/